Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis.

ABSTRACT: Background. Although the benchmark in the treatment of rheumatoid arthritis remains methotrexate, only 70% of patients respond. Thus, there is a need for predictive biomarkers. This study planned to evaluate serum levels of myeloid progenitor inhibitory factor-1 (MPIF-1) and monocyte chemoattractant protein 2 (MCP-2)-as biomarkers. Methods. Patients with rheumatoid arthritis (RA) having high disease activity (DAS28-3v???5.1) were treated with oral methotrexate (MTX) for 12 weeks. Disease activity was measured by DAS28-3v (Modified Disease Activity Score 3 variables). Serum samples were stored at baseline and 12 weeks. Results. This study included 46 patients (F?:?M = 35?:?11) having mean (±SD) age of 42.6 ± 11.3?yrs, disease duration of 4.7 ± 4.5?yrs, and DAS28-3v of 6.1 ± 0.8. Serum MPIF1 was elevated in patients compared to controls (1636.7 ± 1009.7, 441.2 ± 173.8?pg/mL, P < 0.001), but there was no difference in MCP2 levels (31.4 ± 11.9, 33.8 ± 24.0?pg/mL). Baseline MPIF-1 level was lower in good responders (?DAS28-3v???1.2, N = 9) compared to poor responders (?DAS28-3v?

SUBMITTER: Dhir V 

PROVIDER: S-EPMC3886573 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature